# Aln-pnp PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aln-pnp

> The next catalyst for aln-pnp, sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), is its topline data readout, Mar to Jun 2030.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | aln-pnp |
| Codes |  |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | [Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)](https://sec-api.dev/indications/metabolic-dysfunction-associated-steatotic-liver-disease-masld) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Mar to Jun 2030: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07527910 (A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07527910

### March 2030: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07527910 (A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-03-15 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." https://clinicaltrials.gov/study/NCT07527910

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aln-pnp.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Aln-pnp PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aln-pnp

```bibtex
@misc{secapidev_pdufa_aln_pnp_20261116,
  title        = {Aln-pnp PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aln-pnp}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aln_pnp_20261116","title":"Aln-pnp PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aln-pnp","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
